Michael Lübbert, Pierre Wijermans, Michal Kicinski, Sylvain Chantepie, Walter Van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Ollivier Legrand, Robin Foà, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus Posthuma, Mels Hoogendoorn, Anne Giraut, Stéphanie Antunes, Marian Stevens-Kroef, Joop Jansen, Aniek De Graaf, Fabio Efficace, Emanuele Ammatuna, Jean Pierre Vilque, Ralph Wäsch, Heiko Becker, Nicole Blijlevens, Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin A. Huls. "10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group." Blood, 2025. doi:10.1182/blood-2025-1676